202 results about "Antigen recognition" patented technology

The invention belongs to the technical field of data processing, and discloses a dynamic configurable data cleaning method and system based on big data, and the method comprises the steps: collecting a heterogeneous data source, and carrying out the access of the heterogeneous data source in combination with a data source adaptive interface; identifying an abnormal mode in the heterogeneous data source and encoding the abnormal mode into an antigen fingerprint by using a simulated antigen identification memory mechanism; constructing a data value density scoring function based on the antigen fingerprints to obtain a data value density score; constructing a three-dimensional storage topological space according to the data value density score, adopting a lattice migration algorithm, automatically identifying a cold and hot data critical point, triggering hierarchical migration when the temperature of the heterogeneous data source is reduced to a preset temperature threshold value, introducing a thermodynamic diffusion mechanism, and simulating the migration process of the heterogeneous data source in the three-dimensional storage topological space as a thermal diffusion path; and the operation efficiency of the cleaning task is obviously improved.

Various embodiments of the invention provide binding molecules for B-lymphocyte antigen (e.g., CD 19 and CD20), including antigen recognizing receptors (e.g., CARs) that target B-lymphocyte antigens (e.g., CD 19 and CD20). Embodiments of the invention also provide cells expressing such binding molecules, therapeutics compositions comprising such cells, and methods for treating diseases or disorders associated with B-lymphocyte antigen (e.g., CD19 and CD20), including a hematologic cancer, an autoimmune disease (e.g., multiple sclerosis and systemic lupus erythematosus).

The invention provides a specific monoclonal antibody for detecting rotavirus and application of the specific monoclonal antibody, aiming at an epidemic strain of porcine rotavirus, reference to a gene sequence of VP6 protein published by GenBank, antigen epitopes are further optimized, and purified recombinant VP6 protein with antigenicity is obtained for animal immunization. The monoclonal antibody capable of specifically recognizing the porcine rotavirus is successfully screened out. The monoclonal antibody obtained through screening can effectively recognize epidemic strains, has broad-spectrum recognition, is superior to commercially available antibodies, and has high antigen recognition target performance and low non-specificity. And the sequence background is clear, large-scale amplification and production can be carried out, and the method has good commercial value.

The invention relates to an anti-CD276 nano antibody. The anti-CD276 nano antibody comprises a complementary determining region (CDR) and a framework region (FR), wherein the complementarity determining region CDR comprises complementarity determining regions CDR1-CDR3, and the complementarity determining regions CDR1-CDR3 are And the framework region FR comprises framework regions FR1-FR5. The anti-human CD276 nano antibody provided by the invention has the characteristic of immunoreaction with a CD276 antigen, is good in specificity and high in affinity, can be applied to preparation of a CD276 detection reagent or an anti-tumor drug and the like, and can be used as an antigen recognition structural domain of a CAR so as to construct a CAR-T cell; the compound has a remarkable killing effect on a plurality of tumor cell lines expressing CD276 antigens; the anti-human CD276 nano antibody provided by the invention can be used for detecting the expression of CD276 in tumor tissues.

Chimeric antigen receptors that include an antigen recognition domain; a spacer domain derived from a modified immunoglobulin Fc region having one or more mutations in its CH2 region resulting in impaired binding to an FcR; and an intracellular signaling domain.

The invention discloses a type 2 GAstV capsid protein monoclonal antibody and an antigen epitope peptide of the type 2 GAstV capsid protein monoclonal antibody. The monoclonal antibody is prepared by immunizing a mouse with capsid protein GAstV Cap of the type 2 goose astrovirus as an antigen, and is named as 1F1; the monoclonal antibody 1F1 comprises a heavy chain variable region and a light chain variable region, and the amino acid sequences of the heavy chain variable region and the light chain variable region are sequentially shown as SEQ ID No.3 and SEQ ID No.5. In order to determine the B cell antigen epitope of the screened monoclonal antibody, the invention also constructs a GAstV Cap truncated fusion protein, and the antigen recognition epitope is determined through indirect ELISA and Western blotting tests, so that screening is carried out step by step until the shortest linear epitope recognized by the monoclonal antibody is determined, and the amino acid sequence of the shortest linear epitope is shown as SEQ ID No.10. Therefore, the monoclonal antibody and the antigen epitope of the monoclonal antibody can be applied to research on structures and functions of GAstV capsid proteins and preparation of serological diagnostic tools and epitope vaccines.

The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing an antigen recognizing receptor and an inhibitory chimeric antigen receptor (iCAR). Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.

The invention provides an anti-TNF (Tumor Necrosis Factor) alpha nano antibody and application thereof, and relates to a nano antibody, polypeptide containing the nano antibody, application of the nano antibody and the like, a variable region in an amino acid sequence of the nano antibody comprises three complementarity determining regions CDR and a framework region FR, the complementarity determining regions CDR comprise a complementarity determining region CDR1, a complementarity determining region CDR2 and a complementarity determining region CDR3, the main sites participating in antigen recognition and binding are RXXXXXE on CDR1 and ATYSDSPWNXXSFYXLSGVGA on CDR3, and the nano antibody and the polypeptide thereof have very high affinity and activity, can specifically recognize and bind TNF alpha, and can be used for adsorption, removal, detection and the like of TNF alpha.

The invention is directed to a conjugate having the general formula (I)Xn—P—YmBo  (I)with X is an detection moiety,P is a spacer unit,Y an antigen recognizing moiety,B an oligonucleotide comprising 2 to 100 nucleotide residuesand n, m, o are independent integers between 1 and 100wherein P and B are covalently bound to Y and X is covalently bound to P and wherein X is erasable.Further, the invention is directed to a library of such conjugates and a method of detecting target cells utilizing the conjugates or the library of conjugates.

The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.

Provided is a fusion protein, comprising IL-10 and a transmembrane domain, wherein the fusion protein is expressed on an immune cell, and the immune cell does not comprise a regulatory T cell. Also provided is a modified immune cell, comprising a fusion protein and an antigen recognition receptor, wherein the fusion protein comprises IL-10 and a transmembrane domain, and the immune cell does not comprise a regulatory T cell. Also provided is a use of the fusion protein and the modified immune cell in prevention and / or treatment of diseases.

The invention relates to the technical field of biological products, in particular to an indirect ELISA (Enzyme-Linked Immunosorbent Assay) detection kit and a detection method for a goose astrovirus antibody. The kit comprises an elisa plate, an elisa secondary antibody, goose astrovirus positive control serum, goose astrovirus negative control serum, a diluent, a washing solution, a developing solution and a stop solution, wherein a coating antigen of the ELISA plate is a goose astrovirus VP27 recombinant protein, the goose astrovirus is a goose astrovirus GAstV / SD / 36, and the goose astrovirus VP27 recombinant protein corresponds to an ORF2 region. The goose astrovirus GAstV / SD / 36 is used as a template, the virus antigen recognition site VP27 protein is selected as an antigen for preparing the indirect ELISA kit, the indirect ELISA detection kit of the goose astrovirus antibody is prepared, and the accuracy of the detection result of the kit can be improved.

The invention provides a CLL1-targeting enhanced chimeric antigen receptor and application thereof. The CLL1-targeting enhanced chimeric antigen receptor comprises a CLL1-targeting extracellular antigen recognition structural domain, a hinge region, a transmembrane region and an intracellular structural domain, and the intracellular structural domain comprises a costimulatory factor and an intracellular signal transduction structural domain; wherein the intracellular domain further comprises a cytokine receptor gamma chain amino acid sequence derived from IL2R gamma, or wherein the costimulatory domain comprises an amino acid sequence derived from 2B4. Compared with a CLL1CAR-DNT cell with a conventional second-generation chimeric antigen receptor structure, the CLL1CAR-DNT cell with the enhanced chimeric antigen receptor structure has the advantage that the proliferation level of the CLL1CAR-DNT cell with the enhanced chimeric antigen receptor structure is higher.

The present invention relates to immune cells that express immune checkpoint regulators and overcome immune checkpoints, a method for producing the same, and a pharmaceutical composition containing the immune cells. More specifically, the present invention relates to immune cells that are genetically engineered to express an anti-HLA-G soluble scFv that specifically binds to HLA-G, which is an immune checkpoint, together with an antigen recognition receptor, a method for producing the same, and a pharmaceutical composition containing the immune cells. When the anti-HLA-G soluble scFv of the present invention is expressed alone or simultaneously with an antigen recognition receptor in T lymphocytes, natural killer cells, etc., immune cells inhibited by cancer cells expressing immune checkpoints can be activated, and cancer cells can be removed more efficiently. Thereby, activation of endogenous immune cells that have been inhibited by immune checkpoints can also be expected, and thus it can be usefully used as an immunotherapy method for various cancer diseases related to HLA-G.

The present invention discloses a detection substrate, detection method and equipment based on the modification of polymer passivation self-polymerizing thin film coating. A layer of self-polymerizing polymer thin film coating is modified inside the gun head, and the reaction activity is controlled by a passivating agent to reduce the background signal of the actual detection, thereby preparing a gun head modified with a specific antigen / antibody. By using an automated device matched therewith, the following experimental operations can be realized in sequence: immune reaction based on antibody-antigen recognition, washing, incubation of enzyme-labeled antibodies, catalytic signal generation substrate and color signal self-identification reading; in addition, different signal reading probes can be accurately selected, thereby realizing accurate detection according to the content and standard of the object to be detected. The present invention realizes that in the entire detection process, only the relevant corresponding reagent consumables need to be prepared and placed in the corresponding position, and the automatic detection of different objects can be satisfied by setting the corresponding program, and the target content result can be directly obtained. The equipment is portable and can be operated automatically.

The invention belongs to the technical field of medical informatics, and discloses an internal medicine disease treatment scheme optimization system and method based on machine learning, and the system comprises a heterogeneous data monitoring module which is integrated with a multi-source heterogeneous medical database through a standard medical API interface, and extracts and obtains internal medicine disease heterogeneous data; the immune response network module simulates an antigen recognition response mode, constructs a treatment scheme antigen representation matrix according to the internal medicine disease heterogeneous data, recognizes abnormal treatment modes through transfer learning, removes invalid treatment schemes or treatment schemes with side effects corresponding to all the abnormal treatment modes, and then obtains historical effective treatment schemes; a neural symbol memory mechanism is adopted, historical effective treatment scheme fragments are stored, and a treatment scheme variant is constructed based on an adversarial generation mechanism; and the accuracy, individuation and safety of a treatment scheme are improved, so that the treatment effect of internal medicine diseases is remarkably improved, side effects and wrong schemes are reduced, and the development of precise medical treatment is promoted.

The invention belongs to the technical field of cellular immune engineering, and particularly relates to a full-human-derived polypeptide for recognizing CLL-1 and application of the full-human-derived polypeptide. The polypeptide provided by the invention specifically recognizes CLL-1 and has good affinity performance, and the polypeptide specifically targeting CLL-1 provided by the invention can mark CLL-1 positive cells, can be combined with a CLL-1 antigen and the CLL-1 positive cells, and can be used as a detection reagent of CLL-1 molecules and an in-vivo tracing marking reagent. The polypeptide specifically targeting CLL-1 provided by the invention can also be used in an extracellular antigen recognition region of a chimeric antigen receptor, is used in an immune cell treatment drug targeting CLL-1, and is used for killing malignant tumors expressing CLL-1. The polypeptide for specifically recognizing the CLL-1 is a natural full-humanized antibody source, compared with a mouse antibody, a chimeric antibody and a humanized antibody, the immunogenicity of the polypeptide is greatly reduced, and the safety can be guaranteed to the maximum extent in clinical application.

The invention provides a chimeric antigen receptor for regulating and controlling a signal time sequence and application of the chimeric antigen receptor. The chimeric antigen receptor sequentially comprises a signal peptide, an extracellular domain, a transmembrane domain and an intracellular domain from an N terminal to a C terminal, the extracellular structural domain comprises an antigen recognition region and a hinge region; the intracellular domain comprises a costimulatory signal transduction region and a CD3 [zeta] intracellular region variant; the CD3 [zeta] intracellular region variant comprises three ITAMs, and the arrangement sequence of the ITAMs is ITAM3-ITAM2-ITAM1 from the N end to the C end. Compared with a conventional chimeric antigen receptor containing a wild CD3 zeta intracellular region, the chimeric antigen receptor provided by the invention can significantly enhance the functional activity of immune cells expressing the chimeric antigen receptor, which is specifically embodied in stronger multiplication capacity and durability, and significantly improves the antigen sensitivity and targeted killing efficacy.

Various embodiments of the invention provide binding agents for glypican-3 (GPC3), including antibodies or antigen-binding fragments thereof that bind to GPC3 and antigen recognizing receptors (e.g., CARs) that target GPC3 including cells that express GPC3. Embodiments of the i n vention also provide cells comprising such binding agents such as CAR T-cells, therapeutic compositions comprising such cells and methods of using one or more of the binding agents, cells or therapeutic compositions for the treatment of diseases or disorders associated with GPC3 expression such as various neoplastic diseases or disorders (e.g., hepatocellular carcinoma). Various embodiments of the invention also provide methods and systems for treati ng hepatocellular carcinoma (HCC) utilizing a combi nation of radiofrequency (RF) ablation and GPC3-targeted cell therapy. In certain embodiments, immune modulators, such as checkpoint inhibitors, may be co-administered to potentiate immune responses. Additionally, compositions and kits comprising RF ablation devices and GPC3-targeted cell therapy formulations are provided.

A method of treating a disease associated with imbalanced or abnormal activity of MMP-7 is diclosed. The method comprises administration of an antibody comprising an antigen recognition region which binds a catalytic site of MMP-7, having complementarity determining region amino acid sequences as set forth in: SEQ ID NOs: 3, 4 and 5 (CDR3), sequentially arranged from N to C on a light chain of the antibody; and SEQ ID NOs: 6, 7 and 8, sequentially arranged from N to C on a heavy chain of the antibody.

The invention relates inter alia to an antigen recognition construct that binds a specific peptide with a determinable affinity, a T cell receptor with antigen specificity for KRAS, a nucleic acid sequence encoding said antigen recognition construct or said T cell receptor, a vector comprising said nucleic acid sequence, and a host cell comprising said antigen recognition construct or said T cell receptor. The invention also relates to the antigen recognition construct or T cell receptor, the nucleic acid sequence, the vector, or the host cell for use in medicine or in the prevention and / or treatment of disease. Furthermore, the invention relates to methods of treating disease, as well as pharmaceutical compositions and kits.

The present invention belongs to the field of data processing technology. The present invention discloses a dynamic and configurable data cleaning method based on big data and a system thereof. The method comprises collecting heterogeneous data sources and accessing the heterogeneous data sources in combination with a data source adapter interface; utilizing a simulated antigen recognition memory mechanism to identify abnormal patterns in the heterogeneous data sources and encode them into antigen fingerprints; constructing a data value density scoring function based on the antigen fingerprint to obtain a data value density score; constructing a three-dimensional storage topological space according to the data value density score, adopting a lattice migration algorithm to automatically identify the critical points of hot and cold data, triggering hierarchical migration when the heterogeneous data source is cooled to a preset temperature threshold, introducing a thermodynamic diffusion mechanism, and simulating the migration process of the heterogeneous data source in the three-dimensional storage topological space as a heat diffusion path; and significantly improving the operating efficiency of the cleaning task.

Provided are an anti-Her-2 antibody-granulocyte regulatory factor fusion protein, a preparation method therefor and an application thereof. Specifically, this relates to a fusion protein, a single chain of the fusion protein comprising the following elements fused together: (a) a first protein element; (b) a second protein element; and (c) optionally, a joint element located between the first protein element and the second protein element. The first protein element is an antigen recognition module, for example, a protein element of an anti-Her-2 antibody or an active fragment thereof; the second protein element is a granulocyte colony stimulating factor. The present fusion protein has advantages in precise recognition, immunotherapy, controllable toxicity, and enhanced ADCC, and also has the synergistic effect of high-efficiency tumor cell killing activity, as well as low toxicity and side effects.

Disclosed is a nucleic acid encoding a chimeric antigen receptor comprising an extracellular domain including an antigen recognition domain consisting of a fully human single variable heavy chain (VH) domain that binds to a first epitope on B-cell maturation antigen (BCMA), a transmembrane domain, and an intracellular domain including a signaling domain.

Described herein are genetically modified bispecific immune cells such as bicistronic and bivalent immune cells. The bispecific immune cells include an antigen recognition domain that specifically binds a tumor-specific antigen and an antigen recognition domain that specifically binds a radiation-induced cell surface marker. Also described are methods of treating cancer in a subject including administering to the subject a dose of a targeted radionuclide therapy (TRT) agent, and administering to the subject the genetically modified bispecific immune cell.

The present technology provides polypeptides comprising a first immunoglobulin single variable domain (ISVD) binding to albumin, a second ISVD capable of binding to both the constant domain of a human T cell receptor (TCR) on a T cell and the constant domain of a non-human primate TCR on a T cell, wherein said first and second ISVD are linked by a protease cleavable linker, and a targeting moiety. The present technology further provides nucleic acids encoding said polypeptides as well as vectors, hosts and methods to produce these polypeptides. Moreover, the present technology relates to methods for treatment making use of the polypeptides according to the present technology.

This invention belongs to the field of antigen recognition technology, specifically relating to an antibody or its antigen-binding fragment that targets and recognizes mCD155, and its applications. The antibody targeting and recognizing mCD155 includes sequences as shown in SEQ ID NO:8 and SEQ ID NO:16 or as shown in SEQ ID NO:24 and SEQ ID NO:32; it has a strong binding affinity to the mCD155-his protein; and CAR-T cells constructed based on this antibody exhibit excellent killing (apoptotic) activity against mCD155-mediated tumors.

The purpose of the present invention is to provide a polypeptide capable of binding to protein L. Provided is a protein L-binding polypeptide comprising amino acid sequence 1, which is L1 sequence (such as the amino acid sequence represented by SEQ ID NO: 1) - antigen recognition sequence 1 - L2 sequence (such as the amino acid sequence represented by SEQ ID NO: 2) - antigen recognition sequence 2 - L3 sequence (such as the amino acid sequence represented by SEQ ID NO: 3) - antigen recognition sequence 3 - L4 sequence (such as the amino acid sequence represented by SEQ ID NO: 4).

The present application relates to a kind of anti-CD276 nanobody, the anti-CD276 nanobody includes complementary determining region CDR and framework region FR;Wherein, the complementary determining region CDR includes complementary determining region CDR1-CDR3;The framework region FR includes framework region FR1-FR5.The anti-human CD276 nanobody provided by the present application has the immunoreaction characteristic with CD276 antigen, and specificity is good, and affinity is high, can be applied to the preparation of CD276 detection reagent or antitumor drug etc., the anti-human CD276 nanobody provided by the present application can be used as the antigen recognition domain of CAR Then the construction of CAR-T cell, it has significant killing effect to the multiple tumor cell lines of expression CD276 antigen;The anti-human CD276 nanobody provided by the present application can be used to detect the expression of CD276 in tumor tissue.

Provided is a modified regulatory T cell capable of recognizing cells of the liver, capable of treating and / or preventing transplant rejection or immune-mediated damage, and capable of promoting regeneration of cells of the liver.SOLUTION: The present invention provides engineered regulatory T cells (Tregs) comprising a chimeric antigen receptor (CAR), wherein said CAR comprises an antigen recognition domain that specifically binds to the asialoglycoprotein receptor (ASGR). The invention also provides a method of promoting liver tissue repair and / or regeneration in a subject, said method comprising administering to said subject a modified Treg comprising a CAR, or a pharmaceutical composition comprising said modified Treg, wherein said CAR comprises a liver-specific antigen recognition domain.SELECTED DRAWING: None